AstraZeneca rejects Pfizer's "final" bid

Share this article:

Managers from AstraZeneca rebuffed another offer to relinquish their autonomy, saying Pfizer's latest bid for the British drugmaker, a Friday night proposal valued at 69.4 billion pounds ($117 billion), was too low. The rejection of the bid, which Pfizer said was final, left the two drugmakers in a stalemate over a deal that would have created the world's largest drugmaker.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.